Ironwood Pharmaceuticals (IRWD) Operating Expenses (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Operating Expenses data on file, last reported at $33.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 51.7% year-over-year to $33.9 million; the trailing twelve-month figure through Mar 2026 stood at $161.3 million (down 39.05% YoY), and the FY2025 full-year result was $197.6 million, down 23.48% from the prior year.
• Operating Expenses fell to $33.9 million in Q1 2026, from $40.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.2 billion in Q2 2023 to a low of $33.9 million in Q1 2026.
• A 5-year average of $119.9 million and a median of $46.6 million in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 2763.48% in 2023 and sank 94.17% in 2024, its largest moves.
• Tracing IRWD's Operating Expenses over 5 years: stood at $38.8 million in 2022, then surged by 105.9% to $80.0 million in 2023, then retreated by 26.15% to $59.1 million in 2024, then plunged by 30.73% to $40.9 million in 2025, then dropped by 17.04% to $33.9 million in 2026.
• Business Quant data shows IRWD's Operating Expenses at $33.9 million in Q1 2026, $40.9 million in Q4 2025, and $46.6 million in Q3 2025.